孟鲁司特钠片联合沙美特罗替卡松粉吸入剂治疗哮喘—慢性阻塞性肺疾病重叠综合征的临床效果

Clinical Effect of Montelukast Sodium Tablets Combined with Salmeterol Ticasone Powder Inhalation in the Treatment of Asthma-chronic Obstructive Pulmonary Disease Overlap Syndrome

目的 分析孟鲁司特钠片联合沙美特罗替卡松粉吸入剂治疗哮喘-慢性阻塞性肺疾病重叠综合征的临床效果。方法 选择本院2019年1月至2020年1月收治的哮喘-慢性阻塞性肺疾病重叠综合征患者103例,采用随机数法将其分为研究组和对照组,研究组患者54例,对照组患者49例。对照组患者使用常规治疗方式(适当吸氧、支气管扩张剂、雾化治疗等)辅以沙美特罗替卡松粉吸入剂治疗,研究组患者在对照组治疗基础上辅以孟鲁司特钠片。对比两组患者治疗效果、慢性阻塞性肺疾病(CAT)评分和哮喘控制测试(ACT)评分,观察患者治疗前后的差异。结果 研究组患者的治疗效果明显好于对照组患者的治疗效果(P<0.05),研究组患者治疗总有效率为90.74%,对照组患者治疗总有效率为65.30%。研究组CAT评分低于对照组,且ACT评分高于对照组(P<0.05)。结论 使用孟鲁司特钠片联合沙美特罗替卡松粉吸入剂治疗哮喘-慢性阻塞性肺疾病重叠综合征的效果显著,在接受1个疗程治疗后,患者的肺功能均得到了不同程度的升高。

Objective To analyze the clinical effect of montelukast sodium tablet combined with salmeterol ticasone powder inhalation in the treatment of asthma-chronic obstructive pulmonary disease overlap syndrome. Methods A total of 103 patients with asthma-chronic obstructive pulmonary disease overlap syndrome admitted to our hospital from January 2019 to January 2020 were selected and divided into a study group and a control group by random number method. There were 54 patients in the study group and 49 patients in the control group. Patients in the control group were treated with conventional treatment methods(appropriate oxygen inhalation, bronchodilators, nebulization treatment, etc.) supplemented with salmeterol inhaler powder inhalation. Montelukast sodium tablets, and the patients in the study group were supplemented with montelukast sodium tablets on the basis of the control group treatment. The treatment effect between the two groups of patients were compared, chronic obstructive pulmonary disease(CAT) score and asthma control test(ACT) score were compared, to observe the difference between patients before and after treatment. Results After receiving treatment, the patients in the study group who received Montelukast sodium tablets plus salmeterol ticasone powder inhalation were significantly better than the conventional treatment method supplemented with salmeterol ticasone powder inhalation in the control group of patients(P<0.05). The total effective rate of the study group was 90.74%, the total effective rate of the control group was 65.30%,the CAT score of the study group was lower than the control group, and the ACT score was higher than the control group(P<0.05). Conclusion In the treatment of asthma-chronic obstructive pulmonary disease overlap syndrome, the effect of the study group using montelukast sodium tablets combined with salmeterol ticasone powder inhalation is better than that of salmeterol ticasone powder alone in the inhalation control group, after receiving a course of treatment, the patient’s lung scores have been increased to varying degrees, which can improve the patient’s lung function.